Jonathan R. Stretch - Publications

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 06, 2026

Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma.

Journal: Journal of the National Cancer Institute

Published: January 29, 2026

A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making.

Journal: Journal of the American Academy of Dermatology

Published: July 30, 2025

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 27, 2025

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma.

Journal: JAMA dermatology

Published: April 09, 2025

Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patients.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: March 13, 2025

Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial.

Journal: Journal of the American Academy of Dermatology

Published: February 04, 2025

Cartilage Resection in the Surgical Management of Ear Melanoma.

Journal: Annals of surgical oncology

Published: January 06, 2025

Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: October 22, 2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Journal: The New England journal of medicine

Published: June 03, 2024

Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 11, 2024

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 05, 2024